Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 12, 2010, Pages 5323-5328

  Baughn, Anthony D ^a   Deng, Jiaoyu ^a,d   Vilchèze, Catherine ^a   Riestra, Angelica ^a,e   Welch, John T ^b   Jacobs Jr , William R ^a   Zimhony, Oren ^c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d WUHAN INSTITUTE OF VIROLOGY   (China)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLOROPYRAZINAMIDE; BACTERIAL ENZYME; BACTERIAL ENZYME PNCA; BACTERIAL ENZYME PZAA; PYRAZINAMIDE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; DEAMINATION; ENZYME ACTIVITY; GENE MUTATION; GENOTYPE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSPOSON;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENOTYPE; MUTATION; MYCOBACTERIUM BOVIS; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE;

EID: 78649682545     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00529-10     Document Type: Article

References (28)

1. Bardarov, S., S. Bardarov, Jr., M. S. Pavelka, Jr., V. Sambandamurthy, M. Larsen, J. Tufariello, J. Chan, G. Hatfull, and W. R. Jacobs, Jr. 2002. Specialized transduction: an efficient method for generating marked and unmarked targeted gene disruptions in Mycobacterium tuberculosis, M. bovis BCG and M. smegmatis. Microbiology 148:3007-3017.
2. Boshoff, H. I. M., and V. Mizrahi. 2000. Expression of Mycobacterium smegmatis pyrazinamidase in Mycobacterium tuberculosis confers hypersensitivity to pyrazinamide and related amides. J. Bacteriol. 182:5479-5485.
3. Boyer, H. W. and Roulland-Dussoix. 1969. A complementation analysis of the restriction and modification of DNA in Escherichia coli. J. Mol. Biol. 41:459-472.
4. Cynamon, M. H., R. J. Speirs, and J. T. Welch. 1998. In vitro antimycobacterial activity of 5-chloropyrazinamide. Antimicrob. Agents Chemother. 42:462-463.
5. Dye, C., S. Scheele, P. Dolin, V. Pathania, M. C. Raviglione, and for the WHO Global Surveillance and Monitoring Project. 1999. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. JAMA 282:677-686.
6. Ehrt, S., X. V. Guo, C. M. Hickey, M. Ryou, M. Monteleone, L. W. Riley, and D. Schnappinger. 2005. Controlling gene expression in mycobacteria with anhydrotetracycline and Tet repressor. Nucleic Acids Res. 33:e21.
7. Fox, W., and D. A. Mitchison. 1975. Short-course chemotherapy for pulmonary tuberculosis. Am. Rev. Respir. Dis. 111:325-353.
8. Gandhi, N. R., A. Moll, A. W. Sturm, R. Pawinski, T. Govender, U. Lalloo, K. Zeller, J. Andrews, and G. Friedland. 2006. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368:1575-1580.
9. Glover, R. T., J. Kriakov, S. J. Garforth, A. D. Baughn, and W. R. Jacobs, Jr. 2007. The two-component regulatory system senX3-regX3 regulates phosphate-dependent gene expression in Mycobacterium smegmatis. J. Bacteriol. 189:5495-5503.
10. Guo, M., Z. Sun, and Y. Zhang. 2000. Mycobacterium smegmatis has two pyrazinamidase enzymes, PncA and PzaA. J. Bacteriol. 182:3881-3884.
11. Konno, K., F. M. Feldmann, and W. McDermott. 1967. Pyrazinamide susceptibility and amidase activity of tubercle bacilli. Am. Rev. Respir. Dis. 95:461-469.
12. Lee, S., J. Kriakov, C. Vilcheze, Z. Dai, G. F. Hatfull, and W. R. Jacobs. 2004. Bxz1, a new generalized transducing phage for mycobacteria. FEMS Microbiol. Lett. 241:271-276.
13. McDermott, W., and R. Tompsett. 1954. Activation of pyrazinamide and nicotinamide in acidic environments in vitro. Am. Rev. Tuberc. 70:748-754.
14. Ngo, S. C., O. Zimhony, W. J. Chung, H. Sayahi, W. R. Jacobs, Jr., and J. T. Welch. 2007. Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs. Antimicrob. Agents Chemother. 51:2430-2435.
15. Raynaud, C., M. A. Laneelle, R. H. Senaratne, P. Draper, G. Laneelle, and M. Daffe. 1999. Mechanisms of pyrazinamide resistance in mycobacteria: importance of lack of uptake in addition to lack of pyrazinamidase activity. Microbiology 145:1359-1367.
16. Rubin, E. J., B. J. Akerley, V. N. Novik, D. J. Lampe, R. N. Husson, and J. J. Mekalanos. 1999. In vivo transposition of mariner-based elements in enteric bacteria and mycobacteria. Proc. Natl. Acad. Sci. U. S. A. 96:1645-1650.
17. Scorpio, A., and Y. Zhang. 1996. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat. Med. 2:662-667.
18. Simon, R., U. Priefer, and A. Pühler. 1983. A broad host range mobilization system for in vivo genetic engineering: transposon mutagenesis in Gram negative bacteria. Biotechnology 1:784-791.
19. Sun, Z., and Y. Zhang. 1999. Reduced pyrazinamidase activity and the natural resistance of Mycobacterium kansasii to the antituberculosis drug pyrazinamide. Antimicrob. Agents Chemother. 43:537-542.
20. Vilchèze, C., B. Weinrick, K.-W. Wong, B. Chen, and W. R. Jacobs, Jr. 2010. NAD(+) auxotrophy is bacteriocidal for the tubercle bacilli. Mol. Microbiol. doi:10.1111/j.1365-2958.2010.07099.x.
21. Wayne, L. G. 1974. Simple pyrazinamidase and urease tests for routine identification of mycobacteria. Am. Rev. Respir. Dis. 109:147-151.
22. Zhang, Y., and D. Mitchison. 2003. The curious characteristics of pyrazinamide: a review. Int. J. Tuberc. Lung Dis. 7:6-21.
23. Zhang, Y., S. Permar, and Z. Sun. 2002. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J. Med. Microbiol. 51:42-49.
24. Zhang, Y., A. Scorpio, H. Nikaido, and Z. Sun. 1999. Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. J. Bacteriol. 181:2044-2049.
25. Zhang, Y., M. M. Wade, A. Scorpio, H. Zhang, and Z. Sun. 2003. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J. Antimicrob. Chemother. 52:790-795.
26. Zimhony, O., J. S. Cox, J. T. Welch, C. Vilchèze, and W. R. J. Jacobs. 2000. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat. Med. 6:1043-1047.
27. Zimhony, O., C. Vilcheze, M. Arai, J. T. Welch, and W. R. Jacobs, Jr. 2007. Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli. Antimicrob. Agents Chemother. 51:752-754.
28. Zimhony, O., C. Vilchèze, and W. R. Jacobs, Jr. 2004. Characterization of Mycobacterium smegmatis expressing the Mycobacterium tuberculosis fatty acid synthase I (fas1) gene. J. Bacteriol. 186:4051-4055.